Summarized by Masters of Longevity from BioSpace - Funding.
Vitroscope raised $7 million to scale automated perfusion platforms.
Key Takeaways
- Vitroscope has raised $7 million to fund commercialization efforts.
- The platform is sustaining living human tissues for days under perfusion.
- Customer testing of vitro.scale is expected to begin in 2027.
